Royalty Pharma plc (RPRX) KPIs and segments
Close on Nov 18, 2026Market cap $39.49BP/E 39.0Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Royalty Pharma · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Royalty Pharma: 39 chỉ số vận hành, trong đó có Portfolio Receipts, Portfolio Cash Flow và Full-Year Portfolio Receipts Guidance, lấy từ 188 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Income from financial royalty assets($M) | 638 | 595 | 592 | 579 | 550 | 539 | 562 | 533 | 513 | 542 | 523 | ||
Other royalty income and revenues($M) | 36.1 | 35.6 | 29.6 | 30.5 | 28.2 | 28.8 | 31.8 | 31.5 | 24.4 | 26.4 | 73.0 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1 | |||||||||||||
Portfolio Receipts($M)2 | 890 | 773 | 925 | 874 | 814 | 727 | 839 | 742 | 735 | 608 | 717 | 686 | |
Royalty Receipts($M)15 | 883 | 768 | 887 | 856 | 811 | 672 | 788 | 729 | 732 | 605 | 705 | 651 | |
Cystic Fibrosis Franchise (Trikafta / Alyftrek / Symdeko / Orkambi / Kalydeco)($M)4 | 225 | 194 | 253 | 251 | 222 | 194 | 250 | 237 | 207 | 195 | 218 | 207 | |
Trelegy Ellipta($M)4 | 89 | 58 | 98 | 95 | 96 | 57 | 85 | 74 | 91 | 48 | 71 | 60 | |
Tysabri($M)4 | 67 | 67 | 59 | 65 | 68 | 56 | 61 | 61 | 68 | 64 | 69 | 68 | |
Evrysdi($M)4 | 71 | 47 | 80 | 64 | 52 | 33 | 53 | 56 | 48 | 25 | 45 | 20 | |
Xtandi($M)3 | 51 | 44 | 51 | 53 | 50 | 42 | 52 | 46 | 43 | 39 | 41 | 38 | |
Tremfya($M)4 | 79 | 57 | 64 | 56 | 49 | 37 | 36 | 39 | 34 | 30 | 36 | 35 | |
Imbruvica($M)4 | 31 | 36 | 38 | 40 | 41 | 44 | 46 | 46 | 46 | 49 | 50 | 50 | |
Promacta($M)4 | 9 | 8 | 17 | 27 | 38 | 33 | 44 | 44 | 42 | 30 | 43 | 44 | |
Voranigo($M)2 | 55 | 46 | 47 | 39 | 33 | 26 | 20 | 5 | |||||
Cabometyx / Cometriq($M)4 | 24 | 23 | 23 | 22 | 21 | 20 | 21 | 20 | 19 | 17 | 18 | 18 | |
Spinraza($M)4 | 14 | 11 | 12 | 14 | 14 | 12 | 13 | 15 | 14 | 10 | 7 | 17 | |
Trodelvy($M)4 | 16 | 14 | 13 | 12 | 12 | 10 | 13 | 11 | 11 | 10 | 10 | 10 | |
Imdelltra($M)4 | 19 | 17 | 17 | 10 | |||||||||
Amvuttra($M)4 | 10 | 9 | 8 | ||||||||||
Other Commercial Products($M)13 | 121 | 139 | 108 | 109 | 114 | 109 | 96 | 78 | 108 | 88 | 97 | 84 | |
Milestones & Other Contractual Receipts($M) | 7 | 5 | 38 | 18 | 3 | 56 | 51 | 13 | 3 | 3 | 12 | 34 | |
Portfolio Cash Flow($M)7 | 673 | 736 | 722 | 815 | 657 | 641 | 611 | 678 | 617 | 574 | 584 | 637 | |
Credit-Agreement Adjusted EBITDA (Portfolio Liquidity)($M) | 840 | 736 | 889 | 816 | 779 | 633 | 738 | 669 | 679 | 560 | 656 | 632 | |
Payments for Operating & Professional Costs($M)1 | 50 | 37 | 36 | 58 | 34 | 94 | 102 | 72 | 55 | 48 | 61 | 54 | |
Operating & Professional Costs (% of Portfolio Receipts)(%) | 5.6% | 4.8% | 3.9% | 6.7% | |||||||||
Net Interest Paid($M) | 167 | 0 | 167 | 0 | 123 | -8 | 127 | -8 | 62 | -14 | 73 | -5 | |
Distributions to Legacy Non-Controlling Interests — Portfolio Receipts($M) | 93 | 86 | 78 | 79 | 102 | 89 | 85 | 81 | 102 | 92 | 88 | 92 | |
Payments for Employee Equity Performance Awards (EPAs)($M) | 3 | 5 | 10 | 9 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Distributions from Equity Method Investees($M) | 1 | -13 | 42 | 5 | 1 | 63 | 36 | 3 | 11 | 4 | 5 | 5 | |
Proceeds from Available-for-Sale Debt Securities($M) | 6 | 4 | 4 | 3 | 3 | 3 | 13 | 13 | 3 | 3 | 1 | 1 | |
Full-Year Portfolio Receipts Guidance — Upper Bound (Issued in Quarter)($M)5 | 3,550 | 3,500 | 3,450 | 3,425 | 3,250 | 3,150 | 3,125 | 3,050 | 2,800 | 2,775 | 2,700 | ||
Development-Stage Product Candidates in Portfolio | 16 | 19 | 19 | 20 | 17 | 16 | 15 | 14 | 15 | 16 | 15 | 14 | |
Capital Deployment($M)6 | 362 | 349 | 528 | 887 | 1,013 | 595 | 101 | 522 | 1,195 | 951 | 93 | 1,005 | |
Acquisitions of Financial Royalty Assets($M) | 279 | 251 | 452 | 734 | 962 | 1 | 1 | 496 | 1,195 | 729 | 86 | 1,002 | |
Milestone Payments on Acquired Royalties($M) | 13 | 0 | 50 | 3 | 0 | 219 | 50 | 25 | 0 | 50 | 0 | 0 | |
Development-Stage R&D Funding Payments($M) | 70 | 98 | 26 | 51 | 51 | 301 | 51 | 1 | 1 | 1 | 1 | 1 | |
Purchases of Available-for-Sale Debt & Funding Bonds($M) | 0 | 0 | 0 | 100 | 0 | 75 | 0 | 0 | 0 | 150 | 0 | 0 | |
Investments in Equity Method Investees($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 7 | 2 | |
Contributions from Legacy Non-Controlling Interests — R&D($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Announced Royalty Transaction Value — Total($M)2 | 625 | 0 | 1,250 | 1,200 | 1,250 | 2,000 | 250 | 475 | 294 | 1,955 | 94.3 | 1,625 | |
Upfront Consideration Announced($M) | 275 | 0 | 250 | 705 | 960 | 250 | 0 | 475 | 171 | 1,630 | 49.3 | 1,000 | |
Contingent Milestones & Future Funding Announced($M) | 350 | 0 | 1,000 | 495 | 290 | 1,750 | 250 | 0 | 123 | 325 | 45 | 625 | |
Return on Invested Capital (ROIC, LTM)(%)6 | 14.3% | 14.2% | 14.1% | 15.8% | 15.7% | ||||||||
Invested Capital at Work — Average Balance($M) | 22,362 | 22,121 | 21,650 | 21,560 | 20,868 | ||||||||
Invested Capital at Work — Ending Balance($M) | 23,337 | 23,016 | 22,666 | 22,271 | 21,385 | ||||||||
Invested Capital at Work — Beginning Balance($M) | 21,386 | 21,225 | 20,633 | 20,848 | 20,350 | ||||||||
Capital Deployment Added (LTM / Annual)($M) | 2,125 | 2,776 | 3,022 | 2,596 | 2,231 | ||||||||
Expired Royalties Removed from Invested Capital (LTM / Annual)($M) | 174 | 985 | 990 | 1,173 | 1,195 | ||||||||
LTM Credit-Agreement Adjusted EBITDA (ROIC Numerator)($M) | 3,187 | 3,133 | 3,045 | 3,396 | 3,281 | ||||||||
Return on Invested Equity (ROIE, LTM)(%)4 | 20.2% | 20.1% | 19.7% | 22.8% | 22.9% | ||||||||
Invested Equity at Work — Average Balance($M) | 14,098 | 14,162 | 13,997 | 13,844 | 13,322 | ||||||||
Invested Equity at Work — Ending Balance($M) | 15,051 | 14,648 | 14,072 | 13,710 | 13,144 | ||||||||
Net Debt in Invested Equity Schedule($M) | 8,286 | 8,368 | 8,594 | 8,561 | 8,241 | ||||||||
LTM Portfolio Cash Flow (ROIE Numerator)($M) | 2,852 | 2,842 | 2,762 | 3,154 | |||||||||
Total Financial Royalty Assets, Net (Current & Non-Current)($M)4 | 17,079 | 17,082 | 17,322 | 17,063 | 16,624 | 15,977 | 15,749 | 15,911 | 15,734 | 14,640 | 14,126 | 14,827 | |
Financial Royalty Assets — Gross Carrying Value($M)6 | 20,026 | 20,118 | 20,043 | 20,460 | 20,094 | 19,435 | 19,411 | 19,700 | 19,359 | 18,501 | 17,775 | 17,892 | |
Financial Royalty Assets — Net Carrying Value (Before Credit Loss Allowance)($M)6 | 17,372 | 17,341 | 17,527 | 17,275 | 16,844 | 16,194 | 15,973 | 16,149 | 15,936 | 14,808 | 14,263 | 14,965 | |
Cumulative Allowance for Changes in Expected Cash Flows($M)3 | -2,654 | -2,777 | -2,516 | -3,186 | -3,250 | -3,242 | -3,438 | -3,551 | -3,424 | -3,693 | -3,512 | -2,927 | |
Cumulative Allowance for Credit Losses($M)1 | -293 | -259 | -205 | -212 | -221 | -217 | -225 | -238 | -202 | -168 | -137 | -138 | |
Quarterly Current-Period Credit Loss Provision, Net($M) | -34.5 | -8 | 7 | -4 | 7.90 | 13.5 | -33.7 | -30.9 | 0.70 | ||||
GAAP Cash Collections from Financial Royalty Assets (100% Basis)($M)1 | 930 | 815 | 916 | 916 | 882 | 727 | 830 | 778 | 792 | 669 | 745 | 747 | |
Other Consolidated Royalty Cash Collections($M) | 38 | 32.1 | 33.6 | 29.1 | 29.1 | 24.1 | 31.8 | 29.5 | 29.8 | 23.2 | 26.3 | 74.6 | |
Revolution Medicines Co-Funding — Rasonque (Daraxonrasib) Royalty Tranches — Total Commitment($M)3 | 1,000 | 1,250 | 1,250 | 1,250 | 1,250 | 1,250 | |||||||
Revolution Medicines Co-Funding — Senior Term Loan Tranches — Total Commitment($M)3 | 750 | 750 | 750 | 750 | 750 | 750 | |||||||
Teva R&D Co-Funding — TEV-'408 (Vitiligo & Celiac Disease) — Total Commitment($M)3 | 500 | 500 | 500 | ||||||||||
Johnson & Johnson R&D Co-Funding — JNJ-4804 — Total Commitment($M)3 | 500 | 500 | 500 | ||||||||||
Cytokinetics Commercial Launch Funding (Myqorzo / Aficamten) — Total Commitment($M)3 | 450 | 450 | 450 | 450 | 450 | 450 | 450 | 400 | |||||
Biogen Phase 3 R&D Funding — Litifilimab (Lupus) — Total Commitment($M)3 | 250 | 250 | 250 | 250 | |||||||||
Cytokinetics Clinical Development Funding (Omecamtiv Mecarbil) — Total Commitment($M)3 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||
Teva Development Co-Funding — Weltruza (TEV-'749) — Total Commitment($M)3 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||
Total Leverage Ratio (Total Debt / Credit-Agreement Adjusted EBITDA)(×)2 | 2.70 | 2.80 | 2.90 | 3.00 | |||||||||
Net Leverage Ratio (Net Debt / Credit-Agreement Adjusted EBITDA)(×) | 2.50 | 2.60 | 2.70 | 2.80 | |||||||||
Investment-Grade Senior Notes Weighted-Average Duration(năm) | 12.0 | 12.0 | 12.0 | 13.0 | |||||||||
Class A Ordinary Shares Repurchased(M)2 | 1.47 | 0.87 | 1.12 | 2.04 | 4.21 | 8.50 | 22.7 | 1.81 | 3.48 | 3.12 | 0 | 0.96 | |
Weighted-Average Price Paid Per Repurchased Share($) | 59.25 | 52.12 | 44.75 | 36.85 | 36 | 32.58 | 31.92 | 27.78 | 27.40 | 27.08 | 27.32 | ||
Remaining Share Repurchase Authorization($M) | 1,600 | 1,687 | 1,733 | 1,783 | 1,858 | 2,010 | 2,287 | 465 | 516 | 611 | 695 | 695 | |
Biogen Inc. (BIIB) — Tysabri Global Product Revenue (Upstream SEC XBRL)($M)2 | 437 | 451 | 442 | 398 | 432 | 455 | 382 | 415 | 406 | 462 | 431 | 465 | |
United States($M) | 253 | 271 | 242 | 245 | 248 | 272 | 201 | 230 | 228 | 249 | 214 | 248 | |
International (Ex-U.S.)($M) | 184 | 180 | 200 | 153 | 184 | 182 | 181 | 185 | 179 | 214 | 218 | 217 | |
Biogen Inc. (BIIB) — Spinraza Global Product Revenue (Upstream SEC XBRL)($M)2 | 461 | 402 | 374 | 356 | 374 | 393 | 424 | 421 | 381 | 429 | 341 | 413 | |
United States($M) | 246 | 204 | 142 | 169 | 153 | 149 | 154 | 167 | 153 | 157 | 149 | 158 | |
International (Ex-U.S.)($M) | 214 | 198 | 232 | 188 | 221 | 243 | 270 | 255 | 228 | 272 | 193 | 255 | |
Gilead Sciences, Inc. (GILD) — Trodelvy Global Product Revenue (Upstream SEC XBRL)($M)3 | 506 | 457 | 402 | 384 | 357 | 364 | 293 | 355 | 332 | 320 | 309 | 299 | |
United States($M) | 336 | 307 | 253 | 251 | 221 | 224 | 181 | 247 | 226 | 224 | 206 | 226 | |
Europe($M) | 98 | 92 | 95 | 88 | 89 | 96 | 75 | 77 | 80 | 69 | 68 | 48 | |
Rest of World($M) | 71 | 57 | 54 | 45 | 47 | 44 | 37 | 31 | 26 | 26 | 36 | 24 | |
Alnylam Pharmaceuticals, Inc. (ALNY) — Amvuttra Global Product Revenue (Upstream SEC XBRL)($M)3 | 1,130 | 1,012 | 890 | 827 | 685 | 492 | 310 | 287 | 259 | 230 | 195 | 175 | |
United States($M) | 909 | 809 | 703 | 642 | 530 | 361 | 198 | 183 | 169 | 149 | 130 | 122 | |
Europe($M) | 131 | 119 | 113 | 121 | 112 | 92.9 | 80.1 | 69.8 | 65.1 | 56.8 | 43.7 | 30.3 | |
Rest of World (Ex-U.S. & Europe)($M) | 91 | 83.7 | 74.1 | 64 | 43 | 37.7 | 31.9 | 33.4 | 24.8 | 24.9 | 21.3 | 22.8 | |
Exelixis, Inc. (EXEL) — Cabometyx U.S. Net Product Revenue (Upstream SEC XBRL)($M) | 603 | 571 | 553 | 545 | 540 | 518 | 511 | 513 | 476 | 433 | 376 | 428 | |
Total Income & Other Revenues (GAAP)($M)7 | 690 | 674 | 631 | 622 | 609 | 579 | 568 | 594 | 565 | 537 | 568 | 596 | |
Operating Income (GAAP)($M) | 411 | 133 | 563 | 388 | 427 | 210 | 534 | 362 | 735 | 270 | -73.8 | 613 | |
Provision for Changes in Expected Cash Flows & Credit Losses (GAAP)($M) | -34.5 | -8 | 7 | 8.70 | -4 | 7.90 | 13.5 | -36.5 | -33.7 | -30.9 | 0.70 | -53.7 | |
R&D Funding Expense (GAAP)($M) | 63.2 | 97.9 | 39.8 | 50.5 | 50.5 | 301 | 50.5 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | |
General & Administrative Expenses (GAAP)($M) | 150 | 162 | 160 | 164 | 119 | 180 | 111 | 67.6 | 56.7 | 54.7 | 57.7 | 59.2 | |
Net Income Attributable to Royalty Pharma plc (GAAP)($M) | 145 | 17.9 | 295 | 215 | 284 | 32.2 | 239 | 208 | 544 | 102 | 4.80 | 494 | |
Diluted Earnings Per Class A Ordinary Share (GAAP)($) | 0.32 | 0.04 | 0.67 | 0.66 | 0.07 | 0.55 | 1.21 | 0.23 | 0.01 | ||||
Weighted-Average Diluted Class A Shares(M) | 557 | 557 | 557 | 560 | 562 | 578 | 593 | 597 | 598 | ||||
Net Cash Provided by Operating Activities (GAAP)($M)3 | 686 | 729 | 718 | 827 | 703 | 364 | 596 | 743 | 704 | 658 | 665 | 773 | |
Net Cash Used in Investing Activities (GAAP)($M) | -286 | -230 | -478 | -848 | -958 | -312 | 504 | -506 | -1,193 | -893 | -86.6 | -1,000 | |
Net Cash Used in Financing Activities (GAAP)($M) | -699 | -273 | -273 | -300 | 563 | -508 | -941 | -258 | -326 | 1,157 | -212 | -232 | |
Repurchases of Class A Ordinary Shares (GAAP Cash Outflow)($M) | 86.3 | 44.6 | 50.1 | 80.5 | 147 | 292 | 709 | 52.6 | 97 | 80 | 0 | 30.2 | |
Total Assets (GAAP)($M)2 | 19,461 | 19,820 | 19,815 | 19,621 | 19,347 | 18,323 | 17,608 | 18,223 | 18,042 | 17,657 | 16,131 | 16,382 | |
Cash & Cash Equivalents (GAAP)($M) | 514 | 812 | 586 | 619 | 939 | 632 | 1,088 | 929 | 950 | 1,765 | 843 | 477 | |
Total Shareholders' Equity (GAAP)($M) | 9,795 | 9,786 | 9,937 | 9,715 | 9,608 | 9,494 | 9,778 | 10,342 | 10,259 | 9,752 | 9,864 | 10,084 | |
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Royalty Pharma plc operates on a calendar fiscal year ending December 31 and is the largest buyer of biopharmaceutical royalties worldwide. On May 16, 2025, Royalty Pharma completed the internalization of its external manager, RP Management, LLC, onboarding over 100 employees and structurally reducing cash operating and professional costs as a percentage of Portfolio Receipts.
- Under US GAAP (ASC 310), most royalties are accounted for as financial royalty assets using the effective-interest method, where non-cash provisions for changes in expected future cash flows create substantial quarterly volatility in GAAP revenue. Management and credit agreements therefore evaluate operational performance through cash Portfolio Receipts, Royalty Receipts, Credit-Agreement Adjusted EBITDA, and Portfolio Cash Flow.
- Cash royalty receipts generally lag underlying commercial partner end-market drug sales by one calendar quarter (for example, Q2 2026 partner end-market net sales drive Q3 2026 cash royalty collections, while Q3 2026 partner end-market sales provide a direct one-quarter leading indicator for Q4 2026 royalty collections).
- Single-quarter values for footnote-only cumulative schedules (Note 5 allowance additions/reversals and consolidated GAAP cash collections from financial royalty assets) are derived by subtracting prior cumulative year-to-date Form 10-Q figures from current cumulative Form 10-Q or full-year Form 10-K totals.
- Standalone parent-company financial statements of Royalty Pharma plc (an English and Welsh holding company) are prepared annually under UK GAAP (FRS 102) rather than US GAAP and reflect holding-company investments without standalone operating revenue; all operational royalties flow through consolidated subsidiaries.
Không hiện vì thiếu các kỳ gần đây (10)
- Portfolio Receipts, Therapy Royalties & Cash Flow (Key #1) › Portfolio Receipts › Royalty Receipts › Xtandi › Partner-Reported End-Market Net Sales
- Portfolio Receipts, Therapy Royalties & Cash Flow (Key #1) › Portfolio Receipts › Royalty Receipts › Other Commercial Products › Orladeyo › Partner-Reported End-Market Net Sales
- Portfolio Receipts, Therapy Royalties & Cash Flow (Key #1) › Portfolio Receipts › Royalty Receipts › Other Commercial Products › Skytrofa › Partner-Reported End-Market Net Sales
- Portfolio Receipts, Therapy Royalties & Cash Flow (Key #1) › Portfolio Receipts › Royalty Receipts › Other Commercial Products › Yorvipath › Partner-Reported End-Market Net Sales
- Commercial Products in Portfolio Count ('more than 35 commercial products') — Management consistently discloses the total marketed product count as an open lower-bound inequality rather than an exact integer; all 25 named royalty-generating therapies are instead tracked individually under Royalty Receipts.
- Annual Initial Diligence Reviews ('>265' in 2020 to '>480' in 2025) — Reported strictly as lower-bound inequalities ('>') on Deal Funnel slides rather than exact counts; exact downstream funnel stages (CDAs signed, in-depth reviews, proposals submitted, and executed transactions) are included.
- Outbound vs. Inbound Share of In-Depth Reviews (%) — Presentation bar chart prints only one segment label per bar without tabular disclosure of both complementary percentages.
- Note 5 Individual Carrying Values for Tremfya & Trelegy — Tremfya was grouped into 'Other' in Q1 2026 and Trelegy moved into 'Other' in Q2–Q3 2026 as its amortized carrying balance declined below the individual footnote threshold, breaking 3-quarter continuity.
- MorphoSys Development Funding Bonds (Sheet 6 Funding Arrangements) — Fully funded and transitioned to fixed quarterly repayment receipts in Q4 2024, so no longer an active unfunded commitment table entry in 2025–2026.
- Upstream Partner SEC XBRL Product Sales for Vertex (Cystic Fibrosis) & Amgen (Imdelltra) — Latest standardized partner XBRL product breakdown on hand ends in Q2 2026 rather than Q3 2026; partner-reported Q3 2026 end-market sales for both therapies ($3,273M and $406M) are already captured directly under Royalty Pharma's Sheet 4b waterfall.
Dữ liệu cập nhật 2026-11-14.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Portfolio Receipts, Therapy Royalties & Cash Flow (Key #1)
Capital Deployment, Deal Origination & Invested Capital Returns (Key #2)
- Development-Stage Product Candidates in Portfolio21 kỳ
- Blockbuster Therapies in Portfolio (Annual End-Market Sales >$1B)6 kỳ
- Capital Deployment ($M)31 kỳ
- Announced Royalty Transaction Value — Total ($M)27 kỳ
- Return on Invested Capital (ROIC, LTM) (%)7 kỳ
- Return on Invested Equity (ROIE, LTM) (%)7 kỳ
- In-Depth Diligence Reviews Conducted (Annual Deal Funnel)6 kỳ
Financial Royalty Assets Carrying Value, Funding Commitments & Capital Structure
- Total Financial Royalty Assets, Net (Current & Non-Current) ($M)16 kỳ
- GAAP Cash Collections from Financial Royalty Assets (100% Basis) ($M)19 kỳ
- Revolution Medicines Co-Funding — Rasonque (Daraxonrasib) Royalty Tranches — Total Commitment ($M)6 kỳ
- Revolution Medicines Co-Funding — Senior Term Loan Tranches — Total Commitment ($M)6 kỳ
- Teva R&D Co-Funding — TEV-'408 (Vitiligo & Celiac Disease) — Total Commitment ($M)3 kỳ
- Johnson & Johnson R&D Co-Funding — JNJ-4804 — Total Commitment ($M)3 kỳ
- Cytokinetics Commercial Launch Funding (Myqorzo / Aficamten) — Total Commitment ($M)8 kỳ
- Biogen Phase 3 R&D Funding — Litifilimab (Lupus) — Total Commitment ($M)4 kỳ
- Cytokinetics Clinical Development Funding (Omecamtiv Mecarbil) — Total Commitment ($M)8 kỳ
- Teva Development Co-Funding — Weltruza (TEV-'749) — Total Commitment ($M)8 kỳ
- Total Leverage Ratio (Total Debt / Credit-Agreement Adjusted EBITDA) (×)4 kỳ
- Class A Ordinary Shares Repurchased (M)15 kỳ
Workforce, Governance & Sustainability (Internalized Manager & ESG)
External Partner Drug Sales, Regulatory Approvals & Pharmaceutical Benchmarks
- Biogen Inc. (BIIB) — Tysabri Global Product Revenue (Upstream SEC XBRL) ($M)31 kỳ
- Biogen Inc. (BIIB) — Spinraza Global Product Revenue (Upstream SEC XBRL) ($M)31 kỳ
- Gilead Sciences, Inc. (GILD) — Trodelvy Global Product Revenue (Upstream SEC XBRL) ($M)27 kỳ
- Alnylam Pharmaceuticals, Inc. (ALNY) — Amvuttra Global Product Revenue (Upstream SEC XBRL) ($M)21 kỳ
- Exelixis, Inc. (EXEL) — Cabometyx U.S. Net Product Revenue (Upstream SEC XBRL) ($M)31 kỳ
- U.S. FDA CDER Novel Drug Approvals (Annual Industry Benchmark)5 kỳ
- U.S. Producer Price Index — Pharmaceutical Preparation Manufacturing (BLS PCU325412325412)94 kỳ
- U.S. Consumer Price Index — Prescription Drugs (BLS CUUR0000SEMF01)93 kỳ
- U.S. Consumer Price Index — Medical Care Commodities (BLS CUSR0000SAM1)93 kỳ
Consolidated GAAP Financial Context
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Royalty Pharma
- Royalty Pharma Supplemental Financial Information (Q3 2026) ↗
- Royalty Pharma plc Form 10-Q Quarterly Report (rprx-20260930.htm) ↗
- Royalty Pharma plc Form 10-K Annual Report (rprx-20251231.htm) ↗
- Royalty Pharma 2025 Corporate Responsibility Report ↗
- Royalty Pharma plc Form 10-Q (filed 2026-11-04) ↗
- Royalty Pharma plc Form 10-K (filed 2026-02-11) ↗
- BIIB SEC Form 10-Q XBRL Product Revenue (filed 2026-10-28) ↗
- BIIB SEC Form 10-K XBRL Product Revenue (filed 2026-02-06) ↗
- Royalty Pharma plc Form 8-K Earnings Release (rprx-20260930rpplcpressxre.htm) ↗
- Royalty Pharma Corporate Presentation (November 2026) ↗
- Royalty Pharma Quarterly Earnings Presentation (Q3 2026) ↗
- Royalty Pharma Quarterly Earnings Presentation (Q4 2025) ↗
See a number that looks wrong?